Johnson & Johnson

Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.

At 10:07 AM ET today, Abbott Laboratories (NYSE:ABT) stock rose by about 3.9%. The company reported its first-quarter financial results.

Johnson & Johnson stock rose 4.7% as of 12:30 PM ET today. Investors are optimistic about the company’s strong first-quarter results and a dividend hike.

Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.

Johnson & Johnson (NYSE:JNJ) stock has declined by 3.2% since the beginning of 2020. However, the stock has fared better than the broader market.

Abbott Laboratories (NYSE:ABT) stock rose by about 1.0% in extended trading on Thursday. The stock rose 1.3% and closed at $86.04.

Johnson & Johnson (NYSE:JNJ) stock rose immediately after the company announced that an experimental coronavirus vaccine might be available by September.

Overall, tech stocks turned out to be the top performers for 2019. The gain in the technology sector helped the S&P 500 gain 29% in 2019.

If you’re an income investor, I’ve got a strategy for you. Dividend investing is a time-tested way to grow your account over the long haul.

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

At the end of Q3 2019, D.E. Shaw & Co.’s total portfolio of publicly traded securities was worth around $81.2 billion.

In 2019, JNJ stock’s 12% return has lagged the S&P’s 27% return by a wide margin. JNJ has lagged the SPDR S&P Pharmaceuticals ETF (XPH) by 2%.

Johnson & Johnson (JNJ) stock was up 2.9% today as investors reacted positively to the company’s statement about no asbestos in its baby powder.

The Dow Jones Industrial Index (or DJIA) is trading just 2.2% below its all-time high. But is the stock bubble about to burst?

Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.

The Dow Jones Industrial Average Index lost close to 260 points or 0.95% today. Boeing stock (BA) fell 6.73%, the biggest loss in the Dow today.

David Elliot Shaw or D.E. Shaw is a prominent billionaire hedge fund manager and founder of the firm D. E. Shaw & Company.

According to the CDC, about 400,000 people died from opioid overdoses from 1999 to 2017. The number includes deaths from prescription and illegal opioids.

Johnson & Johnson has a much broader revenue base than Teva. The company also has a solid presence in the medical devices and consumer healthcare areas.

Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.

Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.

According to Bloomberg, Johnson & Johnson (JNJ) plans to initiate a trial to evaluate its mosaic-based HIV-1 vaccine in the US and Europe this year.

Today, the Bureau of Labor Statistics released the non-farm payroll data for June. The US economy added 224,000 jobs in the month.

According to Johnson & Johnson’s first-quarter earnings conference call, Erleada gained a four-percentage-point market share in the US on a YoY basis. The drug is now being prescribed equally by urologists and well as oncologists, the two key prescribers for prostate cancer drugs.

Johnson & Johnson’s (JNJ) Pharmaceutical segment is the company’s key revenue driver and accounted for 51.17% of the company’s total revenues in the first quarter. Darzalex, Stelara, Tremfya, and Imbruvica reported double-digit YoY revenue growth in the first quarter.

In its first-quarter earnings press release, Johnson & Johnson (JNJ) has increased its fiscal 2019 adjusted diluted operational EPS guidance from the previously projected $8.65 to $8.80, which implies YoY growth of 5.7%–7.6%, to $8.73–$8.83, which implies a YoY rise of 6.7%–7.9%. The company also increased the lower end and narrowed its fiscal 2019 adjusted diluted EPS guidance from $8.50–$8.65.

In its first-quarter earnings conference call, Johnson & Johnson (JNJ) forecasted a stronger operational revenue growth outlook and expects YoY adjusted operational sales growth of 2.5% to 3.5% and operational sales growth of 0.5% to 1.5% for fiscal 2019. The company has also guided for a YoY reported sales decline of 1.5% to 0.5% for fiscal 2019 based on the euro spot rate of $1.12.

Johnson & Johnson (JNJ) is up by 10.10%, and Gilead Sciences (GILD) is up by 10.92% on a YTD basis. Both the companies are struggling due to intense competitive pressures either from branded or generic competitors. The consensus recommendation for both Johnson & Johnson and Gilead Sciences is a “buy.”

Twitter (TWTR) recently rolled out new reporting tools for its users in India, allowing them to more easily flag misinformation about voting in the country.

In the first quarter, Novartis’s (NVS) Cosentyx reported net sales of $791 million, a YoY (year-over-year) rise of 41% on a constant currency basis.

In the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in worldwide sales.

In the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide revenue on an operational basis.

In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY (year-over-year) rise in ex-US sales.

In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion.

In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide revenues on an operational basis.

Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) decline of 20.6% on a reported basis and 19.1% on an operational basis. According to Johnson & Johnson’s first quarter earnings conference call, despite maintaining volume share of 92% in the infliximab market, Remicade sales […]

Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of 6.9% on a reported basis and 9.6% on an operational basis. The company reported immunology sales worth $2.16 billion in the U.S. market, a YoY rise of 8.1% on a reported and operational basis. […]

EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) has raised the guidance for adjusted diluted operational EPS (earnings per share) from previously projected $8.65 – $8.80 to $8.73 – $8.83. The new guidance excludes the impact of foreign currency fluctuations and implies YoY (year-over-year) growth of 6.7% – 7.9%, instead of […]

Revenue guidance for fiscal 2019 In its first-quarter earnings press release, Johnson & Johnson (JNJ) has raised the guidance for its adjusted operational sales growth rate for fiscal 2019 from previously projected 2.0% – 3.0% to 2.5% – 3.5%. The company has also raised its fiscal 2019 operational sales guidance from $81.6 billion – $82.4 […]

According to Pfizer’s (PFE) fourth-quarter earnings conference call, Xtandi is a pillar of the company’s oncology business.

For Google, the YouTube troubles couldn’t come at a worse time.